Short Androgen Suppression With RT Improves DFS in Localized Prostate Cancer

Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival.
Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival.

Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival (DFS) of patients with intermediate-risk and high-risk cT1b-c to cT2a prostate cancer, a study published in the Journal of Clinical Oncology has shown.1

Because up to 30% of patients who receive radiation for intermediate-risk or high-risk localized prostate cancer relapse biochemically within 5 years, researchers sought to evaluate whether adding androgen suppression for a short duration to primary radiotherapy can improve biochemical disease-free survival in patients with intermediate-risk or high-risk localized disease.

For the study, researchers enrolled 819 patients with stage cT1b-c and a prostate-specific antigen (PSA) 10 ng/mL or higher or Gleason score of 7 or higher, or stage cT2a prostate cancer. Patients were only eligible if they had no involvement of pelvic lymph nodes or clinical evidence of metastasis, and had a PSA 50 ng/mL or less. Of those, 74.8% were intermediate risk and 24.8% were high risk.

Participants were randomly assigned 1:1 to receive radiotherapy or radiotherapy plus 2 depot injections of a luteinizing hormone–releasing hormone agonist on day 1 every 3 months as 6 months of androgen suppression.

RELATED: Opting for Active Surveillance Increasing Among Men With Low-grade Prostate Cancer

Results showed that after a median follow-up of 7.2 years, radiotherapy plus androgen suppression significantly improved biochemical disease-free survival (HR, 0.52; 95% CI: 0.41-0.66; P<.001). Researchers found that adding androgen suppression also improved clinical progression-free survival (Hr, 0.63; 95% CI: 0.48-0.84; P=.001).

Of note, overall survival data are not yet mature.

REFERENCE

1. Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991 [published online ahead of print March 14, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.64.8055.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs